Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are likely to be comparable to those with chemotherapy/ICB combinations (Session ED37).
Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by ge...
Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunot...
Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boos...
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care am...
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes a special panel discussion on ways to eliminate cancer he...